AbbVie Inc.’s newly approved drug Mavyret can treat hepatitis C’s six major strains in eight weeks. It’s also a positive steal in the hepatitis C drug world, at $26,400 for a eight-week ...

AbbVie's Mavyret will likely gain 15%-20% of the global HCV market by 2019. Gilead's HCV revenue will likely decline $1B-1.5B per year starting in 2019.

Approval of Mavyret tablets has been expanded to eight-week treatment for treatment-naive patients with chronic hepatitis C and compensated cirrhosis, the U.S. Food and Drug Administration announced.

--AbbVie today announced that the U.S. Food and Drug Administration approved a label expansion for MAVYRET ®, an oral pangenotypic direct acting antiviral therapy. HCV is a highly infectious ...

Mavyret is the latest drug to treat all six forms of hepatitis C, following Gilead's Epclusa. Earlier drugs generally are limited to patients with just one or a few hepatitis C types or at ...

AbbVie Inc. ( ABBV ) has received approval from the U.S. Food and Drug Administration for the commercialization of its Mavyret, according to the.

Mavyret approved to treat acute hepatitis C in patients, with or without cirrhosis. Eight-week treatment shows 96% cure rate with mostly mild side effects. Tim Melvin’s system has spotted 10X ...

The VOYAGE-1 and VOYAGE-2 trials included HCV genotype 1, 2, 3, 4, or 6 infected patients with cirrhosis (VOYAGE-1) or compensated cirrhosis (VOYAGE-2) who were ...

This photo provided by AbbVie shows the drug Mavyret. On Thursday, Aug. 3, 2017, the Food and Drug Administration approved Mavyret to treat all forms of hepatitis C. The drug works in as little as ...

"The physical, emotional, and economic burden of a curable condition like hepatitis C is far too great in the United States and around the world," said John Ward, M.D., director, Coalition for ...

Mavyret joins two other AbbVie hepatitis C drugs, one from Merck & Co. and four from Gilead Sciences Inc. on the market. That gives doctors and patients more options, ...

Mavyret is now the first eight-week treatment approved for all treatment-naïve adult and certain pediatric patients with HCV genotypes 1-6 both without cirrhosis and with compensated cirrhosis.